Modulatory Effects of 1,25-Dihydroxyvitamin D3 on Human B Cell Differentiation
暂无分享,去创建一个
P. Lipsky | Yue-ying Gu | G. Sims | Shun‐le Chen | Sheng Chen | X. Chen | Sheng Chen | Yue‐ying Gu
[1] H. Pols,et al. Vitamin D , 1928, Calcified Tissue International.
[2] W. Grant,et al. Epidemiology of disease risks in relation to vitamin D insufficiency. , 2006, Progress in biophysics and molecular biology.
[3] S. Harris,et al. Vitamin D and African Americans. , 2006, The Journal of nutrition.
[4] S. Shaftman,et al. Vitamin D deficiency in systemic lupus erythematosus. , 2006, Autoimmunity reviews.
[5] M. Cohen-Lahav. Vitamin D decreases NFB activity by increasing IB levels , 2006 .
[6] P. Lipsky,et al. IL-21 Induces Differentiation of Human Naive and Memory B Cells into Antibody-Secreting Plasma Cells1 , 2005, The Journal of Immunology.
[7] S. Nicosia,et al. Suppression of Death Receptor-mediated Apoptosis by 1,25-Dihydroxyvitamin D3 Revealed by Microarray Analysis* , 2005, Journal of Biological Chemistry.
[8] C. Mathieu,et al. Immunoregulation by 1,25-dihydroxyvitamin D3: Basic concepts , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[9] M. Aringer,et al. New treatments for SLE: cell-depleting and anti-cytokine therapies. , 2005, Best practice & research. Clinical rheumatology.
[10] A. Rolink,et al. Transcriptional networks in developing and mature B cells , 2005, Nature Reviews Immunology.
[11] M. Schurgers,et al. MANAGEMENT OF THERAPY-RESISTANT SYSTEMIC LUPUS ERYTHEMATOSUS WITH RITUXIMAB: REPORT OF A CASE AND REVIEW OF THE LITERATURE , 2005, Acta clinica Belgica.
[12] K. Calame,et al. Regulation of plasma-cell development , 2005, Nature Reviews Immunology.
[13] B. Baslund,et al. Vitamin D3 metabolism in patients with rheumatic diseases: Low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus , 1995, Clinical Rheumatology.
[14] Wei Liu,et al. Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. , 2004, Endocrinology.
[15] J. Pers,et al. Dysfunctional B cells in systemic lupus erythematosus. , 2004, Autoimmunity reviews.
[16] L. Adorini,et al. A Vitamin D Analog Down-Regulates Proinflammatory Chemokine Production by Pancreatic Islets Inhibiting T Cell Recruitment and Type 1 Diabetes Development1 , 2004, The Journal of Immunology.
[17] S. Tangye,et al. Divide and conquer: the importance of cell division in regulating B‐cell responses , 2004, Immunology.
[18] I. Sanz,et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. , 2004, Arthritis and rheumatism.
[19] S. Nicosia,et al. p27Kip1 Stabilization and G1 Arrest by 1,25-Dihydroxyvitamin D3 in Ovarian Cancer Cells Mediated through Down-regulation of Cyclin E/Cyclin-dependent Kinase 2 and Skp1-Cullin-F-box Protein/Skp2 Ubiquitin Ligase* , 2004, Journal of Biological Chemistry.
[20] P. Lipsky,et al. Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus , 2004, Lupus.
[21] R. Wood,et al. DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. , 2004, Physiological genomics.
[22] C. Bingham,et al. Racial, ethnic, and geographic disparities in rates of knee arthroplasty. , 2004, The New England journal of medicine.
[23] P. Kelleher. Autoantibodies before the clinical onset of systemic lupus erythematosus. , 2004, The New England journal of medicine.
[24] P. Lipsky,et al. B cell abnormalities in systemic lupus erythematosus , 2003, Arthritis research & therapy.
[25] R Hal Scofield,et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. , 2003, The New England journal of medicine.
[26] Aristides G. Eliopoulos,et al. Differential Regulation of Vitamin D Receptor and Its Ligand in Human Monocyte-Derived Dendritic Cells1 , 2003, The Journal of Immunology.
[27] M. Worm,et al. 1α,25‐dihydroxyvitamin D3 inhibits anti‐CD40 plus IL‐4‐mediated IgE production in vitro , 2002 .
[28] W. Liu,et al. Vitamin D and Its Analog EB1089 Induce p27 Accumulation and Diminish Association of p27 with Skp2 Independent of PTEN in Pituitary Corticotroph Cells , 2002, Brain pathology.
[29] Andreas Radbruch,et al. Humoral immunity and long-lived plasma cells. , 2002, Current opinion in immunology.
[30] M. Cogswell,et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. , 2002, The American journal of clinical nutrition.
[31] C. Mathieu,et al. Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). , 2002, Diabetes.
[32] D. Joshua,et al. Phenotyping primitive plasma cells , 2002, British journal of haematology.
[33] C. Mathieu,et al. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. , 2002, Trends in molecular medicine.
[34] L. Frati,et al. Negative Regulation of CD95 Ligand Gene Expression by Vitamin D3 in T Lymphocytes1 , 2002, The Journal of Immunology.
[35] Stevan R. Hubbard,et al. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA , 2002, Nature.
[36] M. Worm,et al. 1alpha,25-dihydroxyvitamin D3 inhibits anti-CD40 plus IL-4-mediated IgE production in vitro. , 2002, European journal of immunology.
[37] A. Algra,et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. , 2001, The Journal of rheumatology.
[38] Huub F. J. Savelkoul,et al. 1α,25-Dihydroxyvitamin D3 Has a Direct Effect on Naive CD4+ T Cells to Enhance the Development of Th2 Cells1 , 2001, The Journal of Immunology.
[39] R. Fischer,et al. Knochendichte und 25-OH-Vitamin-D- Serumspiegel bei Patienten mit systemischem Lupus erythematodes , 2001, Zeitschrift für Rheumatologie.
[40] M. Bourgeade,et al. The Expression of p18INK4 and p27kip1 Cyclin-Dependent Kinase Inhibitors Is Regulated Differently During Human B Cell Differentiation1 , 2000, The Journal of Immunology.
[41] N. Kouttab,et al. Vitamin D-mediated gene regulation in phenotypically defined human B cell subpopulations. , 2000, Endocrinology.
[42] C. Mathieu,et al. Identification and immune regulation of 25‐hydroxyvitamin D‐1‐α‐hydroxylase in murine macrophages , 2000, Clinical and experimental immunology.
[43] L. Adorini,et al. 1α,25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation , 2000, The Journal of Immunology.
[44] M. Vaisberg,et al. Influence of cholecalciferol (vitamin D3) on the course of experimental systemic lupus erythematosus in F1 (NZBxW) mice , 2000, Journal of clinical laboratory analysis.
[45] D. Gladman,et al. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. , 1999, Arthritis and rheumatism.
[46] H. DeLuca,et al. Current understanding of the molecular actions of vitamin D. , 1998, Physiological reviews.
[47] G. Studzinski,et al. Lowering of p27Kip1 levels by its antisense or by development of resistance to 1,25-dihydroxyvitamin D3 reverses the G1 block but not differentiation of HL60 cells , 1998, Leukemia.
[48] M. Haussler,et al. The Nuclear Vitamin D Receptor: Biological and Molecular Regulatory Properties Revealed , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[49] M. Cippitelli,et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. , 1998, The Journal of clinical investigation.
[50] M. Hochberg,et al. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.
[51] D. Franklin,et al. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. , 1997, Immunity.
[52] N. Kouttab,et al. 1alpha,25-Dihydroxyvitamin D3 modulates CD38 expression on human lymphocytes. , 1996, Journal of immunology.
[53] Wei Zhang,et al. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. , 1996, Blood.
[54] C. Kwoh,et al. Incidence of systemic lupus erythematosus. Race and gender differences. , 1995, Arthritis and rheumatism.
[55] T. Hickish,et al. The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. , 1993, British Journal of Cancer.
[56] D. Sackett,et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.
[57] P. Lipsky,et al. Generation of nondividing high rate Ig-secreting plasma cells in cultures of human B cells stimulated with anti-CD3-activated T cells. , 1992, Journal of immunology.
[58] K. Bendtzen,et al. The role of monocytes and T cells in 1,25-dihydroxyvitamin D3 mediated inhibition of B cell function in vitro. , 1991, Immunopharmacology.
[59] J F Fries,et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.